Volumetric modulated arc radiotherapy sparing the thyroid gland for early-stage glottic cancer: A dosimetrical analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eun Seok | - |
dc.contributor.author | Yeo, Seung-Gu | - |
dc.date.accessioned | 2021-08-11T22:45:36Z | - |
dc.date.available | 2021-08-11T22:45:36Z | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.issn | 1792-1082 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/12159 | - |
dc.description.abstract | Previous studies on advanced radiotherapy (RT) techniques for early stage glottic cancer have focused on sparing the carotid artery. However, the aim of the present study was to evaluate the dosimetric advantages of volumetric modulated arc therapy (VMAT) in terms of sparing the thyroid gland in early-stage glottic cancer patients. In total, 15 cT1N0M0 glottic cancer patients treated with definitive RT using VMAT were selected, and for dosimetric comparison, a conventional RT plan comprising opposed-lateral wedged fields was generated for each patient. The carotid artery, thyroid gland and spinal cord were considered organs at risk. The prescription dose was 63 Gy at 2.25 Gy per fraction. For the thyroid gland and carotid artery, all compared parameters were significantly lower with VMAT compared with conventional RT. For the thyroid gland, the median reduction rates of the mean dose (D-mean) the volume receiving >= 30% of the prescription dose (V-30) and the V-50 were 32.6, 40.9 and 46.0%, respectively. The D-mean was 14.7 +/- 2.6 Gy when using VMAT compared with 22.2 +/- 3.9 Gy when using conventional RT. The differences between the techniques in terms of planning target volume coverage and dose homogeneity were not significant. When considering a recent normal tissue complication probability model, which indicated the mean thyroid gland dose as the most significant predictor of radiation-induced hypothyroidism, the dosimetric advantage shown in this study may be valuable in reducing hypothyroidism following RT for early stage glottic cancer patients. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Spandidos Publications | - |
dc.title | Volumetric modulated arc radiotherapy sparing the thyroid gland for early-stage glottic cancer: A dosimetrical analysis | - |
dc.type | Article | - |
dc.publisher.location | 그리이스 | - |
dc.identifier.doi | 10.3892/ol.2014.2039 | - |
dc.identifier.scopusid | 2-s2.0-84898856795 | - |
dc.identifier.wosid | 000336555200050 | - |
dc.identifier.bibliographicCitation | Oncology Letters, v.7, no.6, pp 1987 - 1991 | - |
dc.citation.title | Oncology Letters | - |
dc.citation.volume | 7 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1987 | - |
dc.citation.endPage | 1991 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | RADIATION-INDUCED HYPOTHYROIDISM | - |
dc.subject.keywordPlus | NECK-CANCER | - |
dc.subject.keywordPlus | LARYNX CANCER | - |
dc.subject.keywordPlus | CAROTID-ARTERY | - |
dc.subject.keywordPlus | NORMAL TISSUE | - |
dc.subject.keywordPlus | HEAD | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | IRRADIATION | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | carotid artery | - |
dc.subject.keywordAuthor | early stage | - |
dc.subject.keywordAuthor | glottic cancer | - |
dc.subject.keywordAuthor | thyroid gland | - |
dc.subject.keywordAuthor | volumetric modulated arc therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.